| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07391657 A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA)… |
Trial sites expanded: 111 -> 116 locations |
| 2026-06-11 | NCT07227311 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… |
Trial sites expanded: 18 -> 27 locations |
| 2026-06-10 | NCT07532525 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+… |
Recruitment opened |
| 2026-06-10 | NCT07532525 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+… |
date change Primary completion pushed: 2027-07 -> 2027-08 |
| 2026-06-10 | NCT07532525 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+… |
date change Completion pushed: 2028-07 -> 2028-08 |
| 2026-06-06 | NCT04722146 A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple… |
date change Primary completion moved earlier: 2027-04-07 -> 2025-10-13 |
| 2026-06-06 | NCT05438043 A Study of Daratumumab |
date change Completion pushed: 2029-01-31 -> 2029-12-31 |
| 2026-06-06 | NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People… |
Trial sites reduced: 278 -> 271 locations |
| 2026-06-04 | NCT06208150 A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and… |
date change Completion pushed: 2028-03-31 -> 2028-12-31 |
| 2026-06-03 | NCT07227311 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… |
Trial sites expanded: 12 -> 18 locations |
| 2026-06-03 | NCT07096778 Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma |
Trial sites expanded: 11 -> 20 locations |
| 2026-06-03 | NCT06953960 A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone… |
Enrollment increased: 130 -> 199 participants |
| 2026-06-03 | NCT06953960 A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone… |
Trial sites expanded: 32 -> 46 locations |
| 2026-05-28 | NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… |
Recruitment opened |
| 2026-05-28 | NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… |
Trial sites expanded: 0 -> 4 locations |
| 2026-05-28 | NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… |
date change Primary completion moved earlier: 2029-06-29 -> 2028-10-31 |
| 2026-05-28 | NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… |
date change Completion pushed: 2032-12-31 -> 2033-01-31 |
| 2026-05-16 | NCT07227311 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… |
Trial sites expanded: 6 -> 10 locations |
| 2026-05-15 | NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People… |
Trial sites expanded: 131 -> 279 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-09 | NCT07637526 Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed… | Not Yet Recruiting | |
| 2026-05-27 | NCT07609446 Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05730036 | A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab… | Relapsed Refractory Multiple Myeloma (RRMM) | Recruiting |
| NCT07452198 | A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in… | Multiple Myeloma | Recruiting |
| NCT05020236 | A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in… | Multiple Myeloma | Recruiting |
| NCT06413498 | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants… | Multiple Myeloma | Recruiting |
| NCT07138209 | A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or… | Relapsed or Refractory Multiple Myeloma | Recruiting |
| NCT07555938 | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… | Multiple Myeloma | Recruiting |
| NCT07222761 | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination… | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Recruiting |
| NCT06615479 | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in… | Relapsed or Refractory Multiple Myeloma (RRMM) | Recruiting |
| NCT05438043 | A Study of Daratumumab | Multiple Myeloma | Recruiting |
| NCT06152575 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People… | Multiple Myeloma | Recruiting |
| NCT06208150 | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and… | Multiple Myeloma | Recruiting |
| NCT06158841 | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard… | Multiple Myeloma | Recruiting |
| NCT05519085 | A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus… | Relapsed or Refractory Multiple Myeloma | Recruiting |
| NCT07391657 | A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA)… | Relapsed Refractory Multiple Myeloma | Recruiting |
| NCT05572515 | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone… | Relapsed or Refractory Multiple Myeloma | Active, Not Recruiting |
| NCT05083169 | A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara)… | Multiple Myeloma | Active, Not Recruiting |
| NCT04181827 | A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation… | Multiple Myeloma | Active, Not Recruiting |
| NCT05455320 | A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With… | Multiple Myeloma | Active, Not Recruiting |
| Phase 2 | |||
| NCT05922501 | Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma | Relapsed Cancer | Recruiting |
| NCT07523737 | Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory… | Primary Central Nervous System Lymphoma (PCNSL) | Recruiting |
| NCT04508790 | Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory… | Recurrent Plasma Cell Myeloma | Recruiting |
| NCT07096778 | Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | Multiple Myeloma Refractory | Recruiting |
| NCT07018050 | Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma | Relapsed or Refractory Multiple Myeloma | Recruiting |
| NCT07227311 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… | Multiple Myeloma | Recruiting |
| NCT03030261 | Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell… | Multiple Myeloma in Relapse | Active, Not Recruiting |